The interpretation and review of prostate cancer, 2024 ASCO-GU
10.3760/cma.j.cn112330-20240409-00176
- VernacularTitle:2024 ASCO-GU前列腺癌精粹解读
- Author:
Yang LIU
1
;
Liru HE
Author Information
1. 华南恶性肿瘤防治全国重点实验室 广东省恶性肿瘤临床医学研究中心 中山大学肿瘤防治中心放疗科，广州 510060
- Keywords:
Prostate cancer;
Research progress;
Stereotactic body radiation therapy
- From:
Chinese Journal of Urology
2024;45(4):258-260
- CountryChina
- Language:Chinese
-
Abstract:
The 2024 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium presented the latest research advancements in dose escalation and hypofractionation of radical radiotherapy (RT), the challenges associated with post-operative hypofractionated or ultrahypofractionated RT, and the technical developments in RT for prostate cancer. This article aims to interpret and review these significant studies, providing a comprehensive understanding of RT technical advancements, particularly focusing on the application of stereotactic body radiation therapy (SBRT) in localized prostate cancer.
